We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Gsk Plc | GSK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -46.00 | -3.16% | 1,408.50 | 16:29:59 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,455.50 | 1,405.00 | 1,456.50 | 1,408.50 | 1,454.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 11/11/2024 | Interim | GBP | 0.16 | 15/05/2025 | 16/05/2025 | 10/07/2025 |
| 04/12/2023 | Interim | GBP | 0.16 | 20/02/2025 | 21/02/2025 | 10/04/2025 |
| 04/12/2023 | Interim | GBP | 0.15 | 14/11/2024 | 15/11/2024 | 09/01/2025 |
| 04/12/2023 | Interim | GBP | 0.15 | 15/08/2024 | 16/08/2024 | 10/10/2024 |
| 04/12/2023 | Interim | GBP | 0.15 | 16/05/2024 | 17/05/2024 | 11/07/2024 |
| 24/11/2022 | Final | GBP | 0.16 | 22/02/2024 | 23/02/2024 | 11/04/2024 |
| 24/11/2022 | Interim | GBP | 0.14 | 16/11/2023 | 17/11/2023 | 11/01/2024 |
| 24/11/2022 | Interim | GBP | 0.14 | 17/08/2023 | 18/08/2023 | 12/10/2023 |
| 24/11/2022 | Interim | GBP | 0.14 | 18/05/2023 | 19/05/2023 | 13/07/2023 |
| 24/11/2021 | Final | GBP | 0.1375 | 23/02/2023 | 24/02/2023 | 13/04/2023 |
| 24/11/2021 | Interim | GBP | 0.1375 | 17/11/2022 | 18/11/2022 | 12/01/2023 |
| 24/11/2021 | Interim | GBP | 0.1625 | 18/08/2022 | 19/08/2022 | 06/10/2022 |
| 24/11/2021 | Interim | GBP | 0.14 | 19/05/2022 | 20/05/2022 | 01/07/2022 |
| 27/11/2020 | Final | GBP | 0.23 | 24/02/2022 | 25/02/2022 | 07/04/2022 |
| 27/11/2020 | Interim | GBP | 0.19 | 18/11/2021 | 19/11/2021 | 13/01/2022 |
| 27/11/2020 | Interim | GBP | 0.19 | 19/08/2021 | 20/08/2021 | 07/10/2021 |
| 27/11/2020 | Interim | GBP | 0.19 | 20/05/2021 | 21/05/2021 | 08/07/2021 |
| 08/01/2020 | Final | GBP | 0.23 | 18/02/2021 | 19/02/2021 | 08/04/2021 |
| 08/01/2020 | Interim | GBP | 0.19 | 12/11/2020 | 13/11/2020 | 14/01/2021 |
| 08/01/2020 | Interim | GBP | 0.19 | 13/08/2020 | 14/08/2020 | 08/10/2020 |
| Top Posts |
|---|
Posted at 10/7/2025 16:02 by bargainsniper GSK begins shipping influenza vaccine doses for the 2025-26 flu season 07/10/2025 - 09:13 AMÂ GSKÂ supports seasonal flu immunization in the US by shipping FLULAVAL (Influenza Vaccine) and FLUARIX (Influenza Vaccine) in advance of flu seasonPHILADELPHIA-- |
Posted at 03/7/2025 10:24 by tradermichael when the GSK share price was 1,404.50p. It was announced on July 3, 2025, that one of the largest UK-based pharmaceutical corporations, known as GlaxoSmithKline (GSK) intends to launch an impressive investment of 500 million pounds to strengthen its research and development (R&D) activities in the country, reviving its intentions in the biotech industry in the UK. As the UK continues to make adjustments in the move to making London the world capital of life sciences with a market capitalization of about 70 billion pounds, GSK is one of the pillars of the UK life sciences, and the move will serve as a response to the recent fears of large companies quitting the London stock market. With business confidence dwindling in the UK, a country with tremendous potential in relation to developing pharmaceuticals, the investment by GSK is an indication of hope for the UK as a future global pharmaceutical hub.This news was given at the headquarters of GSK in Brentford, and it carries the plans of developing its R&D centre in Stevenage as well as developing new collaborative relations with the UK universities and biotech startups. The strategic push seeks to make the next generation of therapies faster, especially in oncology and infectious diseases, and solidify the brand of the UK in the global biotech challenge. Most of the investment of the amount of 500million will flow to the Stevenage facility of GSK, which is one of the biggest European R&D sites. The company aims at the modernization of its laboratories, combined with the adoption of advanced AI-based drug discovery technologies, and the hiring of 200 more scientists in two years. The decision is an extension of the current capabilities of GSK on vaccine development and precision medicine, specifically to speed up clinical trials with cancer immunotherapies and antiviral therapies. It is believed that the investment will generate 500 supply chain jobs at all stages of supply, including research positions, manufacturing, and so on, giving a needed lift to the British economy. The CEO of GSK, Emma Walmsley, has also noted that the company has been in partnership with the UK on a long-term basis, and such investment shows that GSK is confident of both the scientific talent in the country and its scientific infrastructure. The step is especially notable in light of news concerning other UK powerhouses, what with AstraZeneca et al considering to exchange listings between the UK and the US because of eased regulatory procedures and increased valuations. |
Posted at 27/6/2025 07:57 by tradermichael GlaxoSmithKline (GSK) is conducting a long-term extension study, officially titled ‘Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis.’ The study aims to assess the safety and efficacy of GSK1070806 in individuals who have completed a previous phase 2b study on atopic dermatitis. This research is significant as it could lead to new treatment options for those suffering from moderate to severe atopic dermatitis.The study began on June 5, 2024, with its primary completion and estimated completion dates yet to be disclosed. The most recent update was submitted on June 23, 2025. These dates are crucial as they indicate the progress and current status of the study. |
Posted at 24/6/2025 15:22 by tradermichael GSK plc (GSK, Financial) has received the green light from the U.S. Food and Drug Administration for its 200 mg/mL autoinjector version of Benlysta. This monoclonal antibody specifically inhibits B-lymphocyte stimulators and is designed for subcutaneous injection. It targets patients aged five and above who have active lupus nephritis and are on standard therapies.This approval marks an important step for GSK, as it broadens the treatment options available for children with lupus nephritis. The newly approved autoinjector is a pioneering approach that allows for home administration, making it a first for paediatric patients dealing with systemic lupus erythematosus. GSK first introduced this option for young patients with active systemic lupus erythematosus in 2024. |
Posted at 19/6/2025 09:01 by dope007 All this tarrif stuff and Trump saying they will move production here.From Google AI Glaxo already produce in the USA for the USA AI OverviewGlaxoSmithKl |
Posted at 02/6/2025 11:24 by dplewis1 DUBLIN, June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that it has entered into a definitive agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta ("Trelegy") to GSK (NYSE: GSK) for $225 million in cash."Through this agreement with GSK to monetize our outer-year Trelegy royalties, we are translating our long-standing confidence in Trelegy's sustained success into immediate value for Theravance Biopharma shareholders," said Rick E Winningham, CEO of Theravance Biopharma. "Our initial 2022 sale of Trelegy royalty interests generated $1.1 billion in upfront cash, strengthening our balance sheet and enabling us to return significant capital to shareholders. Our decision to retain future Trelegy royalties and potential milestones in the 2022 transaction reflected our confidence in the product's enduring value and commitment to maximize the value of the royalty interest for our shareholders. This latest agreement with GSK, resulting from the ongoing work of the Strategic Review Committee and the company's senior management, further validates this strategy, and comes alongside our continued work to grow YUPELRI and advance ampreloxetine towards potential regulatory approval and launch."Theravance Biopharma's economic interest in Trelegy originates from a 2002 collaboration agreement with GSK, in which Theravance Biopharma's predecessor pooled with GSK its long-acting beta agonist (LABA) assets in exchange for milestones and royalties on LABA-containing combination products subsequently developed and commercialized by GSK, including Trelegy. In 2022, Theravance Biopharma sold its economic interest in the Trelegy royalties to Royalty Pharma in exchange for $1.1 billion upfront and potential sales related milestone payments of up to $250 million in the aggregate, while retaining the right to receive 85% of Trelegy royalties for sales of Trelegy from and after 2029 (ex-U.S.) and 2031 (U.S.) ("Outer Year Royalties").Under the terms of the agreement announced today, Theravance Biopharma will receive $225 million in cash for the sale of the Outer Year Royalties. The Company retains its right to receive up to $150 million in remaining Trelegy sales related milestones in 2025 and 2026 from Royalty Pharma: -- $50 million if FY 2025 global net sales reach $3.41 billion (approx. -1% vs. 2024) -- $100 million if FY 2026 global net sales reach $3.51 billion (approx. +2% vs. 2024) |
Posted at 02/5/2025 09:19 by tradermichael GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.he new multi-purpose facility will be able to produce sterile liquid vaccines and medicines and will also include an R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK intends to establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. The planned expansion will double the size and capacity of the Marietta site. Regis Simard, president Global Supply Chain, GSK, said: This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next-generation medicines and vaccines to people around the world. We’re grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta site.” Construction of the new facilities is expected to start by the end of this year. According to GSK, the drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028. |
Posted at 14/2/2025 22:47 by pj84 Citadel building a short position won't have helped the share price recently.Ken Griffin’s Citadel bets £300mn against drugmaker GSK Hedge fund’s short position is the biggest in the FTSE 100 group in more than a decade. Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade. Billionaire Ken Griffin’s hedge fund disclosed that it had entered the net short position on Tuesday, with the bet worth 0.51 per cent of the company’s stock, according to data from the Financial Conduct Authority compiled by provider Breakout Point. The last time any firm disclosed a bet against the FTSE 100 pharmaceutical group was in 2013, according to the FCA disclosures. GSK’s shares have risen 11 per cent in the last month, as the drugmaker raised its long-term sales forecast and embarked on a rare £2bn stock buyback earlier this month. GSK reported better than expected earnings on strong sales of HIV and cancer drugs. But the stock has lagged rival pharmaceutical companies, as the drugmaker has failed to excite investors about its pipeline of new medicines and vaccines, which it needs to replace its HIV drugs when they face a patent cliff later in the decade. In the past five years, shares in GSK have fallen 15 per cent, compared with the S&P 500 pharmaceutical index, which rose 45 per cent. Emma Walmsley, GSK’s chief executive, has already faced a battle against an activist investor, when hedge fund Elliott Management built a multibillion-pound stake in the company in 2021. Elliott questioned whether Walmsley was the right leader for the company, given she does not have a scientific background. It also pushed for GSK to consider takeover offers for its consumer health business Haleon, which was later spun off. Analysts at JPMorgan said the fourth-quarter earnings and the company’s guidance for 2025 were “positive&rdqu GSK’s shares collapsed in August 2022 when lawsuits over the heartburn drug Zantac emerged. But when GSK settled the vast majority of cases for $2.2bn in October last year, the shares did not return to their previous level. The company has also suffered from unexpected bad news for two key products. In 2022, GSK withdrew its cancer drug Blenrep from the US market, after a trial did not meet FDA requirements for medicines that had received an accelerated approval. After further studies, the company is now expecting the drug will be reapproved by the regulator by July 2023. Sales of Arexvy, its vaccine for the respiratory syndical virus, known as RSV, dropped in the second half of last year because a US advisory panel unexpectedly recommended limiting its use. Citadel is the world’s top-performing hedge fund according to data from LCH Investments, an investor in hedge funds. The firm houses hundreds of trading teams who bet on a wide variety of assets including equities. Citadel manages $65bn worth of investor capital as of the start of the year, and was up 15.1 per cent in 2024. Citadel declined to comment as the firm does not discuss its positions. GSK did not immediately respond to a request for comment. |
Posted at 07/2/2025 15:50 by dplewis1 THE LAWSUIT: A class action securities lawsuit was filed against GSK plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market "based on information available at the time and correspondence with regulators." GSK also stated that it was "continuing with investigations into the potential source of NDMA." Defendants also assured investors that "GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients," findings that were "consistent with other ranitidine data published prior to 2019." Finally, defendants claimed that they could not "quantify or reliably estimate the liability." These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market. WHAT'S NEXT? If you suffered a loss in GSK stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslr |
Posted at 05/2/2025 16:21 by geckotheglorious II commentGSK annual results get warm reception Trading at the bottom of a long-term trading range, these annual results have given the drug major a much-needed lift. ii's head of results explains why. GSK has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the group’s Vaccines business, which accounts for 29% of overall sales, have weighed heavily on GSK’s recent share price performance on a couple of fronts. Sales fell by 4% in 2024, as had been anticipated, with particular focus on the shingles vaccine Shingrix, which clawed back a deficit to post a gain of just 1%, and respiratory virus vaccine Arexvy, where sales declined by 51% on lower demand due to a limited recommendation from a US advisory committee. In addition, the nomination by President Trump of renowned vaccine sceptic Robert F Kennedy Jr cleared another hurdle yesterday, sending shares of Moderna Inc lower by 6.5% and adding broader weakness to the sector on the potential for both sentiment as well as fundamental concerns. Drug development is in any event a time-consuming, costly and risky endeavour, while there is also increasing evidence of litigation for the unintended side-effects of new products. Slowing some of the gains was the hope that the Food and Drug Administration will continue to be wholly responsible for approving the safety and efficiency of future drugs. However, GSK is far from being a one-trick pony, as evidenced by the performance of a Speciality Medicines unit which is the group’s largest, responsible for 38% of overall sales, where revenue growth of 19% to £11.8 billion provided some welcome relief. Feeding into the promising number were sales growth contributions of 13% from HIV to £7.1 billion, 13% to £3.3 billion for Respiratory/Immunolo The overall result was growth of 7% to £31.4 billion for group sales, marginally ahead of estimates, boosted by a fourth quarter contribution of £8.2 billion, comfortably ahead of the expected £7.8 billion. Immense cash generation of £8 billion and free cash flow of £3 billion showcased the group’s strength, enabling a reduction in net debt from £15 billion to £13 billion in the period. In addition, a share buyback programme of £2 billion was announced which should, all things being equal, support the share price as well as proving management confidence in prospects. Shareholder returns were further bolstered by a planned increase to the dividend which takes the projected yield to 4.6%, a clear attraction for followers of the stock. The shadow of litigation which follows the sector was also seen for GSK in the period, where operating profit fell by 33% in the 12 months ended 31 December to £4.02 billion, largely as a result of the settlement of £1.8 billion relating to its heartburn drug Zantac. Even so, this should now enable a line to be drawn since the vast majority of cases have been settled, and in any event the concerns had already been factored into the share price. More promisingly, GSK’s Research and Development efforts are continuing apace, with the current tally of 71 Speciality and Vaccines products in clinical development a promising sign of things to come. Of these, 19 are in Phase III, or late stage which is the final regulatory hurdle before the products get the full green light. GSK has also been making selective acquisitions over the period which heighten its expertise and focus over the suite of its products. The outlook is relatively upbeat, with turnover growth of between 3% and 5% expected next year, alongside core operating profit growth in the 6% to 8% range. The group’s more recent pipeline progress has also resulted in the sales outlook to 2031 being increased from more than £38 billion to over £40 billion. The shares have had a tumultuous time of late in navigating the actual and potential challenges, and have declined by 14% over the last year, as compared to a gain of 12.6% for the wider FTSE100. By the same token, a five year drop of 26% in the price also leaves the shares on an undemanding valuation in historic terms. Despite the warm reaction to the numbers in opening trade, it seems that a cure for all GSK’s ills may yet be a touch too early to call, with the market consensus of the shares as a hold likely to remain intact for the time being. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
